Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Commitments and Contingencies (Details Textual)

v3.21.1
Note 7 - Commitments and Contingencies (Details Textual)
3 Months Ended
Mar. 16, 2020
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Sublease Income   $ 10,000 $ 10,000
Operating Lease, Payments   $ 34,000 33,000
Operating Lease, Weighted Average Remaining Lease Term (Year)   2 years 2 months 12 days  
Operating Lease, Weighted Average Discount Rate, Percent   9.60%  
License Agreements Expense   $ 38,000 61,000
Research and Development Expense, Total   4,105,000 3,206,000
MD Anderson [Member]      
Research and Development Expense, Total   94,000 179,000
Houston Pharmaceuticals, Inc [Member]      
Related Party Transaction, Expenses from Transactions with Related Party   $ 59,000 $ 108,500
Houston Pharmaceuticals, Inc [Member] | Consulting Agreement on Licensed Molecules [Member]      
Other Commitments, Number of Agreements 2    
Other Commitment, Total $ 43,500    
Houston Pharmaceuticals, Inc [Member] | Agreement Providing Access to Laboratory Equipment [Member]      
Other Commitment, Total $ 15,000    
Other Commitments, Cancellation Period (Day) 60 days